AstraZeneca two-in-one drug succeeds in lung disease test

LONDON, March 18 (Reuters) - AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials, boosting hopes for the company's respiratory pipeline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.